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To the Editor,

 {#jmv25820-sec-0010}

Testing for SARS‐CoV‐2 RNA has become the standard for COVID‐19 diagnosis.[^1^](#jmv25820-bib-0001){ref-type="ref"}, [^2^](#jmv25820-bib-0002){ref-type="ref"} However, a number of false negative results have been reported,[^2^](#jmv25820-bib-0002){ref-type="ref"} resulting in a failure to quarantine infected patients. If unchecked, this could cause a major setback in containing viral transmission.[^3^](#jmv25820-bib-0003){ref-type="ref"}

Titers of SARS‐CoV‐2 antibodies can reflect the progress of viral infection. Around 60 convalescent patients (with an onset time of 6‐7 weeks) in a ward in the Wuhan Tongji Hospital were tested for specific antibodies against SARS‐CoV‐2. All patients tested positive for the IgG against the virus, while 13 patients tested negative for immunoglobulin M (IgM), with the immunoglobulin G (IgG) titer being greater than the IgM titer (Table [1](#jmv25820-tbl-0001){ref-type="table"} and Figure [1](#jmv25820-fig-0001){ref-type="fig"}). Meanwhile, the IgM and IgG titers in 10 convalescent patients were tested twice (1 week apart); both titers showed a decrease, with the IgG titer being greater than the IgM titer (Table [2](#jmv25820-tbl-0002){ref-type="table"} and Figure [1](#jmv25820-fig-0001){ref-type="fig"}). In these patients, two consecutive SARS‐CoV‐2 RNA tests were negative and the chest computed tomography findings indicated improvement. Considering this, their antibody titers and consistent clinical manifestations suggested that antibody detection could act as an indicator of the stage of COVID‐19 progression and that the antibodies in convalescent patients are not always maintained at a high level. The immune status fitted both, the clinical and general characteristics of the humoral response. In one report, while 38 patients in the acute phase of the infection tested positive for SARS‐CoV‐2, 31 (81.6%) of them tested negative for IgM and IgG in serological assays,[^4^](#jmv25820-bib-0004){ref-type="ref"} thereby demonstrating that these patients were in the early stages of infection, as both the antibody titers were relatively low (Supplemental table [1](#jmv25820-tbl-0001){ref-type="table"}). COVID‐19 patients will develop immunity after recovery; however, the persistence, attenuation, and duration of protection of SARS‐CoV‐2 antibodies requires further investigation.[^5^](#jmv25820-bib-0005){ref-type="ref"}

###### 

Serological data from 60 convalescent patients in the Wuhan Tongji Hospital

  Patients   Onset       Tested on   IgM titer, AU/mL   IgG titer, AU/mL
  ---------- ----------- ----------- ------------------ ------------------
  1          13/1/2020   9/3/2020    29.26 (+)          231.67 (+)
  2          22/1/2020   3/3/2020    33.71 (+)          198.77 (+)
  3          15/1/2020   9/3/2020    17.17 (+)          464.69 (+)
  4          24/1/2020   9/3/2020    63.54 (+)          178.23 (+)
  5          22/1/2020   9/3/2020    15.36 (+)          369.07 (+)
  6          12/1/2020   8/3/2020    50.01 (+)          203.07 (+)
  7          30/1/2020   9/3/2020    58.26 (+)          203.00 (+)
  8          17/1/2020   9/3/2020    41.21 (+)          405.85 (+)
  9          5/2/2020    9/3/2020    12.41 (+)          175.03 (+)
  10         4/2/2020    10/3/2020   13.47 (+)          31.60 (+)
  11         15/1/2020   12/3/2020   20.90 (+)          162.72 (+)
  12         10/2/2020   12/3/2020   18.32 (+)          192.90 (+)
  13         18/1/2020   9/3/2020    99.85 (+)          220.03 (+)
  14         27/1/2020   10/3/2020   21.88 (+)          139.36 (+)
  15         17/1/2020   9/3/2020    76.84 (+)          177.61 (+)
  16         1/2/2020    9/3/2020    123.06 (+)         161.16 (+)
  17         26/1/2020   8/3/2020    16.45 (+)          194.57 (+)
  18         27/1/2020   8/3/2020    115.23 (+)         194.80 (+)
  19         20/1/2020   9/3/2020    36.49 (+)          96.75 (+)
  20         23/1/2020   9/3/2020    27.08 (+)          136.96 (+)
  21         18/1/2020   9/3/2020    176.27 (+)         369.4 (+)
  22         28/1/2020   9/3/2020    82.71 (+)          177.69 (+)
  23         3/2/2020    9/3/2020    65.15 (+)          241.57 (+)
  24         24/1/2020   9/3/2020    47.84 (+)          200.31 (+)
  25         26/1/2020   8/3/2020    63.52 (+)          165.49 (+)
  26         21/1/2020   8/3/2020    164.18 (+)         346.98 (+)
  27         20/1/2020   9/3/2020    168.04 (+)         171.85 (+)
  28         22/1/2020   8/3/2020    99.28 (+)          137.58 (+)
  29         26/1/2020   8/3/2020    66.79 (+)          188.75 (+)
  30         3/2/2020    8/3/2020    27.13 (+)          208.82 (+)
  31         2/2/2020    6/3/2020    55.03 (+)          186.47 (+)
  32         3/2/2020    5/3/2020    164.96 (+)         180.42 (+)
  33         27/1/2020   6/3/2020    84.12 (+)          162.14 (+)
  34         26/1/2020   9/3/2020    287.54 (+)         299.75 (+)
  35         22/1/2020   9/3/2020    346.62 (+)         962.01 (+)
  36         28/1/2020   9/3/2020    163.58 (+)         733.95 (+)
  37         20/1/2020   8/3/2020    150.93 (+)         158.48 (+)
  38         20/1/2020   8/3/2020    114.81 (+)         338.99 (+)
  39         27/1/2020   9/3/2020    176.29 (+)         206.03 (+)
  40         23/1/2020   9/3/2020    147.93 (+)         965.24 (+)
  41         16/1/2020   6/3/2020    45.35 (+)          134.35 (+)
  42         20/1/2020   8/3/2020    78.34 (+)          112.56 (+)
  43         24/1/2020   6/3/2020    307.14 (+)         420.72 (+)
  44         27/1/2020   8/3/2020    181.75 (+)         1077.09 (+)
  45         26/1/2020   6/3/2020    41.68 (+)          233.06 (+)
  46         26/1/2020   8/3/2020    20.1 (+)           162.79 (+)
  47         25/1/2020   6/3/2020    155.64 (+)         279.45 (+)
  48         24/1/2020   3/2/2020    8.82 (‐)           170.22 (+)
  49         1/2/2020    14/3/2020   8.91 (‐)           73.35 (+)
  50         30/1/2020   8/3/2020    7.33 (‐)           185.74 (+)
  51         27/1/2020   9/3/2020    2.59 (‐)           133.14 (+)
  52         30/1/2020   8/3/2020    5.65 (‐)           121.43 (+)
  53         30/1/2020   9/3/2020    5.53 (‐)           20.2 (+)
  54         23/1/2020   14/3/2020   9.15 (‐)           191.61 (+)
  55         12/1/2020   12/3/2020   3.65 (‐)           15.16 (+)
  56         26/1/2020   10/3/2020   4.12 (‐)           25.61 (+)
  57         24/1/2020   7/3/2020    3.4 (‐)            213.32 (+)
  58         20/1/2020   11/3/2020   3.16 (‐)           183.32 (+)
  59         23/1/2020   4/3/2020    5.01 (‐)           208.08 (+)
  60         20/1/2020   8/3/2020    6.75 (‐)           150.80 (+)

*Note*: (+) positive result; (‐) negative result; titer ≤10 AU/mL indicates a negative result according to the manufacturer\'s instructions.

Abbreviations: AU, arbitrary unit; IgG, immunoglobulin G; IgM, immunoglobulin M.
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![IgM and IgG antibodies level to SARS‐CoV‐2 from the onset of symptoms. IgG, immunoglobulin G; IgM, immunoglobulin M](JMV-9999-na-g001){#jmv25820-fig-0001}

###### 

Serological data from 10 convalescent patients who were tested twice (1 week apart)

  Patients   Onset       1st Test   2nd Test    IgM titer (1st test), AU/mL   IgM titer (2nd test), AU/mL   IgG titer (1st test), AU/mL   IgG titer (2nd test), AU/mL
  ---------- ----------- ---------- ----------- ----------------------------- ----------------------------- ----------------------------- -----------------------------
  38         20/1/2020   8/3/2020   15/3/2020   114.81 (+)                    36.14 (+)                     338.99 (+)                    210.33 (+)
  39         27/1/2020   9/3/2020   16/3/2020   176.29 (+)                    50.21 (+)                     206.03 (+)                    88.74 (+)
  40         23/1/2020   9/3/2020   16/3/2020   147.93 (+)                    40.35 (+)                     965.24 (+)                    201.34 (+)
  41         16/1/2020   6/3/2020   13/3/2020   45.35 (+)                     13.54 (+)                     134.35 (+)                    50.33 (+)
  42         20/1/2020   8/3/2020   15/3/2020   78.34 (+)                     21.36 (+)                     112.56 (+)                    47.21 (+)
  43         24/1/2020   6/3/2020   14/3/2020   307.14 (+)                    80.79 (+)                     420.72 (+)                    97.06 (+)
  44         27/1/2020   8/3/2020   15/3/2020   181.75 (+)                    47.03 (+)                     1077.09 (+)                   242.25 (+)
  45         26/1/2020   6/3/2020   15/3/2020   41.68 (+)                     12.36 (+)                     233.06 (+)                    95.15 (+)
  46         26/1/2020   8/3/2020   15/3/2020   20.1 (+)                      9.28 (‐)                      162.79 (+)                    88.68 (+)
  47         25/1/2020   6/3/2020   12/3/2020   155.64 (+)                    48.49 (+)                     279.45 (+)                    200.58 (+)

*Note*: (+) positive result; (‐) negative result; titer ≤10 AU/mL indicates a negative result according to the manufacturer\'s instructions.

Abbreviations: AU, arbitrary unit; IgG, immunoglobulin G; IgM, immunoglobulin M.
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Presently, data regarding the COVID‐19 spectrum are mainly focused on clinical infection with respiratory symptoms. The proportion of subclinical infections and atypical patients remains unknown. Antibody detection will help in the profiling of the COVID‐19 spectrum. Epidemiological surveys of serum antibody levels in the population would help in fully understanding how many people have ever been infected. This information will allow the determination of the proportion of different types of infected individuals and a profiling of the complete disease spectrum of COVID‐19.

High virus volumes and transmission have been reported in the asymptomatic phase.[^6^](#jmv25820-bib-0006){ref-type="ref"} By combining the results of RNA and antibody testing, we can further identify the contribution of different types of infected people (especially the atypical ones and those with subclinical infection) in the spread of the virus and the disease. This will provide a key scientific basis for the discovery and management of infectious sources.

Detection of IgM and IgG against SARS‐CoV‐2 is a fast and simple screening method. As an effective supplement to RNA testing, antibody detection is of epidemiological significance and is an important means to understand the occurrence, development, prognosis, and outcome of COVID‐19. More medical research on the expression levels of antibodies against SARS‐CoV‐2 and on the prognosis of COVID‐19 is required.
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